Thermo Fisher Scientific Opens Call for Grant Proposals to Fund Clinical Research in Hematology-oncology

Thermo Fisher Scientific Opens Call for Grant Proposals to Fund Clinical Research in Hematology-oncology CARLSBAD, Calif., Sept. 29, 2021 /PRNewswire/ — To support clinical research needs using next-generation sequencing (NGS), Thermo Fisher Scientific today announced it is accepting new submissions for its Oncomine Clinical Research Grant. The latest call for proposals aims to provide funding for... Read more

GE Healthcare Unveils Next-Gen Fixed X-ray System Definium Tempo to Reduce Burnout and Improve Workflow and Productivity for Overburdened Radiology Departments

Waukesha, WI – September 28, 2021 – GE Healthcare introduced the Definium Tempo, a new fixed, overhead tube suspension (OTS) digital X-ray system designed to be a “personal assistant” to radiologists and technologists – leveraging automation to reducing workflow burdens and help radiology departments deliver the best patient care possible. Definium Tempo is designed to... Read more

Roche launches three respiratory test panels on cobas 6800/8800 Systems in CE markets to help identify multiple pathogens with overlapping symptoms in patients

Acute respiratory infections are one of the leading causes of death and disability globally, presenting substantial health challenges especially for infants, the elderly and the immunocompromised.1-3 Three new molecular diagnostic test panels for influenza and other common respiratory illnesses can be run together or alone using one patient sample. Flexible syndromic testing tailored to patient... Read more

PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend

WALTHAM, Mass.–(BUSINESS WIRE)–Sep. 17, 2021– PerkinElmer, Inc. (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents for a total consideration of approximately $5.25 billion. The acquisition, the largest in PerkinElmer’s history, further expands the... Read more

FDA Approves Tissue-Based NGS Companion Diagnostic for Takeda's Targeted Therapy for NSCLC Patients with EGFR Exon20 Insertion Mutations

FDA Approves Tissue-Based NGS Companion Diagnostic for Takeda’s Targeted Therapy for NSCLC Patients with EGFR Exon20 Insertion Mutations Oncomine Dx Target Test now approved as CDx for five targeted NSCLC therapies in the U.S. CARLSBAD, Calif., Sept. 15, 2021 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher... Read more

Speeding up Breast Cancer Diagnosis in Egypt: GE Healthcare, Gustave Roussy and the Egypt Ministry of Health Partner to Create Rapid Breast Cancer Diagnosis Clinics

Cairo, Egypt and Villejuif & Buc, France – September 7, 2021 – GE Healthcare, Gustave Roussy and the Egypt Ministry of Health (MOH) signed a preliminary agreement leveraging Gustave Roussy’s One Stop Breast Cancer diagnostics program to increase the speed and the accuracy of breast cancer diagnosis in Egypt. Breast cancer is the most common... Read more

Roche to present data from industry leading portfolio at ESMO 2021 showing significant progress in early stage and uncommon cancers

First data to be presented from the phase II coopERA Breast Cancer study evaluating neoadjuvant giredestrant treatment for oestrogen receptor (ER)-positive, HER2-negative breast cancer New data from the phase III IMpower010 study provide further insights into the role of Tecentriq® (atezolizumab) in early-stage non-small cell lung cancer (NSCLC) Genomic data from the phase II CUPISCO... Read more

The Intricate Network of Immune Cells Revealed by Multiplex Tissue Microscopy

When our immune systems identify invaders – such as parasites, bacteria or viruses – it can spark inflammation, which brings fluid and immune cells to the area of infection. While this can be very effective in battling infection, it also has collateral damage on nearby healthy tissues. In our daily lives, just by eating or... Read more

Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy

Cancer is the second leading cause of death worldwide, with nearly 10 million deaths annually.1, 2 In the U.S., approximately 1.9 million new cancer cases are expected to be diagnosed in 2021.1 Based on cancer biomarkers, the first-of-its-kind VENTANA MMR RxDx Panel helps determine which solid tumour patients may benefit from GSK immunotherapy. Roche/GSK collaboration... Read more

[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care

Pivotal phase III POLARIX trial comparing Polivy in combination with chemotherapy regimen R-CHP versus the standard of care R-CHOP in treatment of first-line diffuse large B-cell lymphoma (DLBCL) met its primary endpoint of investigator-assessed progression-free survival Prolonging survival without disease advancement could be transformative for newly diagnosed DLBCL patients as currently 40% of patients relapse... Read more